Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CPRX

Catalyst Pharmaceuticals Inc

Nov 29 • 04:00PM ET

14.05

Dollar change -0.16
Percentage change -1.13	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	26.65	EPS (ttm)	0.53	Insider Own	14.03%	Shs Outstand	105.26M	Perf Week	2.26%
Market Cap	1.50B	Forward P/E	10.99	EPS next Y	1.28	Insider Trans	0.00%	Shs Float	91.65M	Perf Month	15.16%
Income	62.04M	PEG	-	EPS next Q	0.28	Inst Own	69.83%	Short Float / Ratio	7.26% / 5.49	Perf Quarter	-2.70%
Sales	348.39M	P/S	4.30	EPS this Y	-21.07%	Inst Trans	10.29%	Short Interest	6.66M	Perf Half Y	21.65%
Book/sh	3.27	P/B	4.30	EPS next Y	115.88%	ROA	16.62%	Target Price	23.30	Perf Year	-14.80%
Cash/sh	1.13	P/C	12.38	EPS next 5Y	-	ROE	20.06%	52W Range	11.09 - 22.11	Perf YTD	-24.46%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	17.63%	52W High	-36.45%	Beta	1.10
Dividend %	-	Quick Ratio	3.17	Sales past 5Y	4089.61%	Gross Margin	79.66%	52W Low	26.69%	ATR	0.51
Employees	82	Current Ratio	3.32	Sales Q/Q	79.39%	Oper. Margin	21.79%	RSI (14)	61.05	Volatility	2.49% 3.71%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	-242.15%	Profit Margin	17.81%	Rel Volume	0.89	Prev Close	14.21
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 08 AMC	Payout	0.00%	Avg Volume	1.21M	Price	14.05
Recom	1.40	SMA20	6.07%	SMA50	9.60%	SMA200	0.48%	Volume	1,077,447	Change	-1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral	$10 → $15.50
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral	$6 → $1
Sep-30-14	Reiterated	ROTH Capital	Buy	$5 → $6
Sep-16-14	Reiterated	ROTH Capital	Buy	$3.50 → $5
Sep-15-14	Reiterated	H.C. Wainwright	Buy	$5 → $13
Oct-21-13	Reiterated	Aegis Capital	Buy	$4 → $5.50
Sep-24-13	Initiated	Maxim Group	Buy	$4
Sep-06-13	Reiterated	Aegis Capital	Buy	$3.50 → $4
Apr-18-13	Initiated	Aegis Capital	Buy	$2.50
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform	$3.70
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform	$9
Jan-31-07	Initiated	Stifel Nicolaus	Buy	$9
Jan-05-07	Initiated	First Albany	Buy	$10

Show Previous Ratings

Nov-16-23 08:05AM	Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-09-23 06:10AM	Catalyst: Q3 Earnings Snapshot (Associated Press Finance)
Nov-08-23 04:11PM	Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Nov-02-23 10:37AM	Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE (GlobeNewswire)
10:00AM	Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
10:01AM	Loading…
Nov-01-23 10:01AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-30-23 08:03AM	Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo (GlobeNewswire)
Oct-26-23 03:19PM	Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals (GlobeNewswire)
Oct-23-23 08:03AM	Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023 (GlobeNewswire)
Oct-19-23 08:03AM	Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer (GlobeNewswire)
Oct-16-23 08:03AM	Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida (GlobeNewswire)
Oct-13-23 08:03AM	Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE (GlobeNewswire)
Oct-12-23 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:40AM	This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar (Zacks)
Sep-18-23 08:03AM	Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
11:30AM	Loading…
Sep-08-23 11:30AM	Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report? (Zacks)
Sep-06-23 01:06PM	Unraveling the Future of Catalyst Pharmaceuticals Inc (CPRX): A Deep Dive into Key Metrics (GuruFocus.com)
Aug-16-23 10:56AM	Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer (GlobeNewswire)
Aug-14-23 08:05AM	Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress (GlobeNewswire)
Aug-11-23 06:09AM	Catalyst Pharmaceuticals Second Quarter 2023 Earnings: EPS: US$0.35 (vs US$0.21 in 2Q 2022) (Simply Wall St.)
Aug-09-23 05:50PM	Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:41PM	Catalyst: Q2 Earnings Snapshot (AP Finance)
04:17PM	Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-23 02:44PM	7 Strong Buy Value Stocks You Should Be Loading Up On Now (InvestorPlace)
Jul-25-23 08:03AM	Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End (GlobeNewswire)
Jul-24-23 08:03AM	Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-23-23 10:21AM	Will Weakness in Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Prove Temporary Given Strong Fundamentals? (Simply Wall St.)
Jul-19-23 06:00AM	Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals (GlobeNewswire)
Jul-05-23 05:50PM	Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know (Zacks)
Jul-02-23 01:46PM	7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing (InvestorPlace)
05:50PM	Loading…
Jun-29-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-23-23 05:50PM	Catalyst Pharmaceutical (CPRX) Gains As Market Dips: What You Should Know (Zacks)
Jun-21-23 08:00PM	CPRX: Raising target price to $14.00 (Argus Research)
Jun-20-23 06:00AM	Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals (GlobeNewswire)
Jun-19-23 09:30AM	Catalyst (CPRX) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Jun-14-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-09-23 11:30AM	Catalyst (CPRX) Down 16.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 09:30AM	Wall Street Analysts See Catalyst (CPRX) as a Buy: Should You Invest? (Zacks)
08:03AM	Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023 (GlobeNewswire)
May-30-23 08:03AM	Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors (GlobeNewswire)
May-22-23 08:15AM	Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy? (Motley Fool)
May-12-23 09:30AM	Should You Invest in Catalyst (CPRX) Based on Bullish Wall Street Views? (Zacks)
May-11-23 08:41AM	Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) high institutional ownership speaks for itself as stock continues to impress, up 5.5% over last week (Simply Wall St.) -19.19%
May-10-23 05:55PM	Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates (Zacks)
04:53PM	Catalyst: Q1 Earnings Snapshot (AP Finance)
04:27PM	Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year (GlobeNewswire)
May-09-23 08:03AM	Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day (GlobeNewswire)
May-03-23 05:45PM	Catalyst Pharmaceutical (CPRX) Stock Moves -0.12%: What You Should Know (Zacks)
May-01-23 08:03AM	Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report (GlobeNewswire) +6.41%
Apr-27-23 05:45PM	Catalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-26-23 08:00PM	CPRX: Lowering target price to $17.00 (Argus Research)
12:45PM	3 Reasons Growth Investors Will Love Catalyst (CPRX) (Zacks)
Apr-24-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
08:03AM	Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-20-23 12:26PM	We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease (Simply Wall St.)
08:03AM	Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting (GlobeNewswire)
Apr-18-23 05:50PM	Catalyst Pharmaceutical (CPRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-14-23 11:30AM	Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue? (Zacks)
05:05AM	Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains? (Zacks)
Apr-12-23 05:50PM	Catalyst Pharmaceutical (CPRX) Flat As Market Sinks: What You Should Know (Zacks)
Apr-11-23 09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
Apr-07-23 07:30AM	7 A-Rated Stocks to Buy for April 2023 (InvestorPlace)
Apr-05-23 10:15AM	2 Top Growth Stocks That Can Withstand an Economic Downturn (Motley Fool)
Apr-04-23 05:50PM	Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know (Zacks)
10:23AM	1 Growth Stock to Buy Before the Next Bull Market (Motley Fool)
Apr-03-23 12:45PM	Here is Why Growth Investors Should Buy Catalyst (CPRX) Now (Zacks)
09:00AM	Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock (Zacks)
Mar-27-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
07:12AM	Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 574% (Simply Wall St.)
Mar-22-23 09:55AM	Wall Street Analysts Think Catalyst (CPRX) Could Surge 26.44%: Read This Before Placing a Bet (Zacks)
Mar-21-23 05:50PM	Catalyst Pharmaceutical (CPRX) Gains But Lags Market: What You Should Know (Zacks)
09:00AM	Is Trending Stock Catalyst Pharmaceuticals, Inc. (CPRX) a Buy Now? (Zacks)
Mar-17-23 09:30AM	Is It Worth Investing in Catalyst (CPRX) Based on Wall Street's Bullish Views? (Zacks)
Mar-16-23 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Catalyst (CPRX) (Zacks) +9.83%
Mar-15-23 05:25PM	Catalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:11PM	Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-13-23 06:30AM	7 Core Stocks to Build a Solid Portfolio Around (InvestorPlace)
Mar-10-23 09:00AM	Catalyst Pharmaceuticals, Inc. (CPRX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Mar-09-23 10:00AM	MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Mar-08-23 11:20AM	Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies (GlobeNewswire)
10:00AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Mar-01-23 08:03AM	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023 (GlobeNewswire)
Feb-28-23 06:30AM	7 Smart Stock Picks for Cautious Investors (InvestorPlace)
Feb-27-23 05:50PM	Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know (Zacks)
12:10PM	Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:00AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
09:00AM	Catalyst Pharmaceuticals, Inc. (CPRX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Feb-24-23 12:45PM	Is Catalyst (CPRX) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Feb-22-23 08:03AM	Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day (GlobeNewswire)
Feb-21-23 05:50PM	Catalyst Pharmaceutical (CPRX) Stock Moves -1.74%: What You Should Know (Zacks)
Feb-15-23 09:30AM	Is Catalyst (CPRX) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
09:00AM	Investors Heavily Search Catalyst Pharmaceuticals, Inc. (CPRX): Here is What You Need to Know (Zacks)
Feb-13-23 05:50PM	Catalyst Pharmaceutical (CPRX) Gains But Lags Market: What You Should Know (Zacks)
07:36AM	Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
Feb-08-23 12:45PM	Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks) -5.61%
Feb-07-23 08:03AM	Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance (GlobeNewswire)
Feb-06-23 05:50PM	Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know (Zacks)
05:14PM	The 7 Best Growth Stocks to Buy for February 2023 (InvestorPlace)
Feb-03-23 09:00AM	Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock (Zacks)
Jan-30-23 05:50PM	Catalyst Pharmaceutical (CPRX) Gains As Market Dips: What You Should Know (Zacks)

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DENKHAUS DONALD A	Director	Aug 03	Option Exercise	1.13	60,000	67,800	393,000	Aug 04 05:00 PM
MCENANY PATRICK J	President and CEO	May 16	Option Exercise	0.79	173,849	137,341	4,119,285	May 17 05:04 PM
MCENANY PATRICK J	President and CEO	May 15	Option Exercise	0.79	26,151	20,659	3,971,587	May 17 05:04 PM
MCENANY PATRICK J	President and CEO	May 15	Sale	13.23	26,151	345,978	3,945,436	May 17 05:04 PM
Daly Richard J	Director	May 12	Option Exercise	0.79	50,000	39,500	148,000	May 16 05:01 PM
Miller Steve	Chief Operating Officer	May 11	Option Exercise	0.79	100,000	79,000	687,457	May 12 05:00 PM
Tierney David S	Director	May 11	Option Exercise	0.79	20,000	15,800	333,541	May 12 05:01 PM
COELHO PHILIP H	Director	May 04	Option Exercise	0.79	50,000	39,500	204,887	May 05 05:00 PM
Tierney David S	Director	Apr 05	Option Exercise	0.79	30,000	23,700	343,541	Apr 07 05:00 PM
Tierney David S	Director	Apr 05	Sale	16.83	30,000	504,900	313,541	Apr 07 05:00 PM
Del Carmen Jeffrey	Chief Commercial Officer	Mar 29	Option Exercise	3.18	40,000	127,063	28,524	Mar 30 05:01 PM
GRANDE ALICIA	VP, Treasurer and CFO	Mar 29	Option Exercise	1.13	50,000	56,500	100,557	Mar 30 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Mar 29	Sale	16.70	50,000	835,100	50,557	Mar 30 05:00 PM
Del Carmen Jeffrey	Chief Commercial Officer	Mar 29	Sale	16.70	40,000	667,810	7,541	Mar 30 05:01 PM
GRANDE ALICIA	VP, Treasurer and CFO	Mar 28	Option Exercise	0.79	58,216	45,991	108,773	Mar 30 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Mar 28	Sale	16.54	58,216	962,786	50,557	Mar 30 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Mar 22	Option Exercise	0.79	41,784	33,009	89,081	Mar 24 05:00 PM
GRANDE ALICIA	VP, Treasurer and CFO	Mar 22	Sale	16.50	41,784	689,528	50,557	Mar 24 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Mar 20	Option Exercise	1.13	50,000	56,500	188,076	Mar 22 04:45 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Mar 20	Sale	16.07	50,000	803,450	138,076	Mar 22 04:45 PM
DENKHAUS DONALD A	Director	Jan 24	Option Exercise	0.79	50,000	39,500	329,000	Jan 27 04:30 PM
O'Keeffe Charles B	Director	Jan 24	Option Exercise	0.79	50,000	39,500	616,391	Jan 27 04:30 PM
INGENITO GARY	Chief Medical Officer	Dec 06	Sale	16.85	5,918	99,718	30,802	Dec 08 05:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CPRX

Catalyst Pharmaceuticals Inc

Upgrade your FINVIZ experience